Vermillion Company Profile (NASDAQ:VRML)

About Vermillion (NASDAQ:VRML)

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Diagnostics & Testing
Sub-Industry: N/A
Symbol: NASDAQ:VRML
CUSIP: N/A
Web: www.vermillion.com

Capitalization:

Market Cap: $72.45 million
Outstanding Shares: 56,164,000

Average Prices:

50 Day Moving Avg: $1.34
200 Day Moving Avg: $1.74
52 Week Range: $0.76 - $2.85

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -8.06
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $3.05 million
Price / Sales: 23.75
Book Value: $0.08 per share
Price / Book: 16.13

Profitability:

EBIDTA: ($10,500,000.00)
Net Margins: -372.05%
Return on Equity: -215.26%
Return on Assets: -121.77%

Debt:

Debt-to-Equity Ratio: 0.34%
Current Ratio: 3.21%
Quick Ratio: 3.16%

Misc:

Average Volume: 40,223 shs.
Beta: 2.42
Short Ratio: 16.56

Frequently Asked Questions for Vermillion (NASDAQ:VRML)

What is Vermillion's stock symbol?

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). The company earned $0.90 million during the quarter. Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%. View Vermillion's Earnings History.

Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?

1 analysts have issued 12 month target prices for Vermillion's shares. Their predictions range from $1.75 to $1.75. On average, they anticipate Vermillion's stock price to reach $1.75 in the next year. View Analyst Ratings for Vermillion.

Who are some of Vermillion's key competitors?

Some companies that are related to Vermillion include Invuity (IVTY), Peregrine Pharmaceuticals (PPHM), Quorum Health Corporation (QHC), GTx (GTXI), Majesco Entertainment Company (COOL), Neovasc (NVCN), ProQR Therapeutics N.V. (PRQR), T2 Biosystems (TTOO), Axsome Therapeutics (AXSM), Nuvectra Corporation (NVTR), Novelion Therapeutics (NVLN), Oramed Pharmaceuticals (ORMP), SeaSpine Holdings Corporation (SPNE), Trinity Biotech PLC (TRIB), Sorrento Therapeutics (SRNE), Cidara Therapeutics (CDTX), Intec Pharma (NTEC) and Cumberland Pharmaceuticals (CPIX).

Who are Vermillion's key executives?

Vermillion's management team includes the folowing people:

James T. LaFrance, Chairman of the Board
Valerie Barber Palmieri, President, Chief Executive Officer
Fred Ferrara, Chief Operating Officer
Donald G. Munroe Ph.D., Senior Vice President - Business Development, Chief Scientific Officer
Eric J. Schoen, Chief Accounting Officer, Vice President - Finance
James S. Burns, Independent Director
Veronica G. H. Jordan Ph.D., Independent Director
David R Schreiber, Independent Director
Carl Severinghaus, Independent Director
Eric K. Varma M.D., Independent Director

Who owns Vermillion stock?

Vermillion's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.36%), Birchview Capital LP (4.07%), Vanguard Group Inc. (1.03%), Cannell Peter B & Co. Inc. (0.60%), M&T Bank Corp (0.41%) and Trellus Management Company LLC (0.21%). Company insiders that own Vermillion stock include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan. View Institutional Ownership Trends for Vermillion.

Who sold Vermillion stock? Who is selling Vermillion stock?

Vermillion's stock was sold by a variety of institutional investors in the last quarter, including Birchview Capital LP and Trellus Management Company LLC. View Insider Buying and Selling for Vermillion.

Who bought Vermillion stock? Who is buying Vermillion stock?

Vermillion's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Vermillion stock in the last two years include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan. View Insider Buying and Selling for Vermillion.

How do I buy Vermillion stock?

Shares of Vermillion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vermillion's stock price today?

One share of Vermillion stock can currently be purchased for approximately $1.29.

MarketBeat Community Rating for Vermillion (NASDAQ VRML)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		64 (Vote Outperform)
Underperform Votes:		43 (Vote Underperform)
Total Votes:		107

MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Vermillion (NASDAQ:VRML) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Buy Rating
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$1.75 (35.66% upside)

Analysts' Ratings History for Vermillion (NASDAQ:VRML)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price	Details
8/30/2017	Canaccord Genuity	Reiterated Rating	Buy	$2.50 -> $1.75	Low

(Data available from 9/20/2015 forward)

Earnings History for Vermillion (NASDAQ:VRML)

Earnings by Quarter for Vermillion (NASDAQ:VRML)

Earnings History by Quarter for Vermillion (NASDAQ VRML)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/9/2017	Q2 2017	($0.04)	($0.04)		$0.90 million	View	Listen
5/18/2017	Q1 2017	($0.04)	($0.05)		$0.73 million	View	N/A
11/10/2016	Q316	($0.06)	($0.07)		$0.62 million	View	N/A
8/10/2016	Q216	($0.09)	($0.07)		$0.71 million	View	Listen
5/16/2016	Q116	($0.09)	($0.09)		$0.51 million	View	Listen
3/24/2016	Q415		($0.10)	$1.20 million	$0.36 million	View	Listen
11/12/2015	Q315	($0.10)	($0.10)	$0.57 million	$0.33 million	View	Listen
8/13/2015	Q215	($0.08)	($0.11)	$1.50 million	$535.00 million	View	Listen
5/11/2015	Q115	($0.10)	($0.10)	$0.81 million	$0.95 million	View	Listen
3/25/2015	Q414	($0.08)	($0.11)	$1.59 million	$1.57 million	View	Listen
11/14/2013	Q3		($0.10)	$319.00 million	$330.00 million	View	Listen
8/14/2013	Q2 2013		($0.11)	$0.32 million	$0.23 million	View	Listen
5/15/2013	Q1 2013	($0.15)	($0.17)	$0.30 million	$0.33 million	View	Listen
11/12/2012	Q312	($0.21)	($0.13)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Vermillion (NASDAQ:VRML)

Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS

Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Vermillion (NASDAQ:VRML)

Insider Ownership Percentage: 3.67%
Institutional Ownership Percentage: 35.57%

Institutional Ownership by Quarter for Vermillion (NASDAQ:VRML)

Insider Trades by Quarter for Vermillion (NASDAQ:VRML)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/15/2017	Valerie Barber Palmieri	Insider	Buy	719	$1.39	$999.41
8/23/2017	Valerie Barber Palmieri	Insider	Buy	768	$1.30	$998.40
5/17/2017	Valerie Barber Palmieri	Insider	Buy	555	$1.80	$999.00
2/17/2017	Larry N Feinberg	Insider	Buy	617,731	$1.40	$864,823.40
2/13/2017	Eric Schoen	SVP	Buy	3,347	$1.40	$4,685.80
2/13/2017	Jack W Schuler	Major Shareholder	Buy	974,081	$1.40	$1,363,713.40
2/13/2017	Valerie Barber Palmieri	CEO	Buy	10,042	$1.40	$14,058.80
2/13/2017	Veronica Gh Jordan	Director	Buy	6,695	$1.40	$9,373.00
1/28/2016	Jack W Schuler	Major Shareholder	Buy	1,493	$1.60	$2,388.80
1/25/2016	Jack W Schuler	Major Shareholder	Buy	3,700	$1.57	$5,809.00
1/21/2016	Jack W Schuler	Major Shareholder	Buy	30,700	$1.46	$44,822.00
1/19/2016	Jack W Schuler	Major Shareholder	Buy	57,749	$1.45	$83,736.05
1/15/2016	Jack W Schuler	Major Shareholder	Buy	8,400	$1.56	$13,104.00
7/14/2015	Larry N Feinberg	Insider	Buy	512,043	$1.96	$1,003,604.28
12/23/2014	Jack W Schuler	Major Shareholder	Buy	1,288,339	$1.44	$1,855,208.16
12/23/2014	Larry N Feinberg	Insider	Buy	972,222	$1.44	$1,399,999.68
12/19/2014	Peter S Roddy	Director	Buy	16,502	$1.44	$23,762.88
11/21/2014	Valerie Barber Palmieri	COO	Buy	3,500	$1.51	$5,285.00
11/20/2014	James T Lafrance	Insider	Buy	27,907	$1.44	$40,186.08
11/20/2014	Valerie Barber Palmieri	COO	Buy	30,000	$1.44	$43,200.00
11/19/2014	James T Lafrance	Insider	Buy	41,615	$1.43	$59,509.45
11/18/2014	Eric Schoen	CAO	Buy	5,000	$1.42	$7,100.00
11/20/2013	William B Creech	VP	Buy	2,000	$2.33	$4,660.00
6/11/2013	William B Creech	VP	Buy	10,000	$3.18	$31,800.00

(Data available from 1/1/2013 forward)

Headline Trends for Vermillion (NASDAQ:VRML) Latest Headlines for Vermillion (NASDAQ:VRML)

Source:

Date	Headline
	ETFs with exposure to Vermillion, Inc. : September 19, 2017 finance.yahoo.com - September 19 at 8:30 PM
	Vermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 finance.yahoo.com - September 19 at 9:22 AM
	Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell finance.yahoo.com - September 1 at 10:56 AM
	Vermillion, Inc. (VRML) Receives "Buy" Rating from Canaccord Genuity www.americanbankingnews.com - August 30 at 4:56 PM
	Critical Analysis: Vermillion (VRML) & CareDx (CDNA) www.americanbankingnews.com - August 25 at 2:12 PM
	CareDx (CDNA) vs. Vermillion (VRML) Critical Comparison www.americanbankingnews.com - August 18 at 10:46 AM
	Edited Transcript of VRML earnings conference call or presentation 9-Aug-17 8:30pm GMT finance.yahoo.com - August 13 at 7:34 AM
	Vermillion, Inc. (VRML) Releases Quarterly Earnings Results, Hits Estimates www.americanbankingnews.com - August 10 at 6:21 PM
	Vermillion Reports Second Quarter 2017 Results finance.yahoo.com - August 10 at 9:32 AM
	Vermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference Call finance.yahoo.com - August 5 at 8:22 AM
	Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th finance.yahoo.com - August 2 at 8:35 AM
	Financial Survey: Veracyte (VCYT) and Vermillion (NASDAQ:VRML) www.americanbankingnews.com - August 1 at 8:46 AM
	Analyzing Veracyte (VCYT) & Vermillion (VRML) www.americanbankingnews.com - July 31 at 2:23 PM
	Vermillion, Inc. (NASDAQ:VRML) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - July 28 at 10:26 PM
	Vermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8th finance.yahoo.com - July 28 at 9:47 AM
	Vermillion (NASDAQ:VRML) vs. InVitae Corp (NVTA) Head-To-Head Survey www.americanbankingnews.com - July 24 at 2:14 PM
	Vermillion (VRML) vs. Lion Biotechnologies (IOVA) Head-To-Head Comparison www.americanbankingnews.com - July 20 at 6:27 PM
	Vermillion, Inc. (NASDAQ:VRML) Receives Average Recommendation of "" from Analysts www.americanbankingnews.com - July 17 at 8:14 PM
	Critical Survey: Vermillion (VRML) vs. InVitae Corp (NVTA) www.americanbankingnews.com - July 14 at 12:08 AM
	ETFs with exposure to Vermillion, Inc. : July 11, 2017 finance.yahoo.com - July 12 at 9:05 AM
	Affymetrix (AFFX) versus Vermillion (VRML) Critical Contrast www.americanbankingnews.com - July 1 at 10:04 PM
	Vermillion, Inc. (VRML) Upgraded at ValuEngine www.americanbankingnews.com - June 2 at 8:04 PM
	Vermillion, Inc. (VRML) Short Interest Up 10.5% in May www.americanbankingnews.com - May 28 at 7:06 AM
	ETFs with exposure to Vermillion, Inc. : May 15, 2017 finance.yahoo.com - May 15 at 7:44 PM
	Vermillion, Inc. :VRML-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 finance.yahoo.com - May 12 at 3:29 PM
	Vermillion, Inc. (VRML) Issues Earnings Results www.americanbankingnews.com - May 12 at 12:38 PM
	Investor Network: Vermillion, Inc. to Host Earnings Call finance.yahoo.com - May 12 at 4:13 AM
	Vermillion Reports First Quarter 2017 Results finance.yahoo.com - May 12 at 4:13 AM
	Vermillion reports 1Q loss finance.yahoo.com - May 12 at 4:13 AM
	Edited Transcript of VRML earnings conference call or presentation 11-May-17 12:30pm GMT finance.yahoo.com - May 12 at 4:13 AM
	Vermillion (VRML) Receiving Positive Press Coverage, Analysis Shows www.americanbankingnews.com - May 3 at 3:52 PM
	Vermillion, Inc. (VRML) Short Interest Update www.americanbankingnews.com - April 29 at 7:06 AM
	Vermillion (VRML) Getting Favorable Media Coverage, Report Shows www.americanbankingnews.com - April 28 at 1:38 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vermillion, Inc. - (VRML) finance.yahoo.com - April 28 at 10:34 AM
	Vermillion to Report First Quarter 2017 Financial Results and Host Investor Conference Call on May 11 finance.yahoo.com - April 26 at 5:09 PM
	Somewhat Negative News Coverage Extremely Likely to Affect Vermillion (VRML) Stock Price www.americanbankingnews.com - April 25 at 3:30 PM
	Vermillion (VRML) Getting Negative Media Coverage, Report Finds www.americanbankingnews.com - April 19 at 8:23 AM
	After raising $2 million, Austin's Consortia Health tackles problems that might make some blush www.bizjournals.com - April 15 at 7:00 PM
	ETFs with exposure to Vermillion, Inc. : April 5, 2017 finance.yahoo.com - April 7 at 1:24 PM
	VERMILLION, INC. Files SEC form 10-K, Annual Report biz.yahoo.com - April 1 at 9:38 AM
	Edited Transcript of VRML earnings conference call or presentation 29-Mar-17 8:30pm GMT finance.yahoo.com - March 30 at 8:18 AM
	ASPiRA Labs Announces TriCare South Contract finance.yahoo.com - March 30 at 8:18 AM
	Q4 2016 Vermillion Inc Earnings Release - Before Market Open biz.yahoo.com - March 29 at 10:17 AM
	Vermillion Announces Publication of Ovarian Cancer Symptoms Index Study finance.yahoo.com - March 29 at 10:17 AM
	Vermillion, Inc. (VRML) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - March 28 at 8:23 AM
	Vermillion to Report Fourth Quarter and Full Year 2016 Financial Results and Host Investor Conference Call on March 29, 2017 finance.yahoo.com - March 16 at 6:31 AM
	VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits biz.yahoo.com - March 13 at 8:09 PM
	Vermillion, Inc. (VRML) Sees Large Decline in Short Interest www.americanbankingnews.com - March 13 at 8:23 AM
	ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1® Access to Over 12 Million Beneficiaries finance.yahoo.com - March 6 at 7:53 PM
	VERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers biz.yahoo.com - March 4 at 3:56 AM

Vermillion (VRML) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff

Vermillion Company Profile (NASDAQ:VRML)

About Vermillion (NASDAQ:VRML)

What is Vermillion's stock symbol?

How were Vermillion's earnings last quarter?

Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?

Who are some of Vermillion's key competitors?

Who are Vermillion's key executives?

Who owns Vermillion stock?

Who sold Vermillion stock? Who is selling Vermillion stock?

Who bought Vermillion stock? Who is buying Vermillion stock?

How do I buy Vermillion stock?

What is Vermillion's stock price today?

Analyst Ratings

Earnings

Estimates

Dividends

Insider Trades

Headlines

Social

Chart